-
1دورية أكاديمية
المؤلفون: Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K, CLEAR Trial Investigators
المساهمون: Gennigens, Christine
المصدر: New England Journal of Medicine, 384 (14), 1289 - 1300 (2021-04-08)
مصطلحات موضوعية: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Phenylurea Compounds, Programmed Cell Death 1 Receptor, Protein Kinase Inhibitors, Quinolines, Everolimus, pembrolizumab, lenvatinib, Sunitinib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized/administration & dosage, Antibodies, Monoclonal, Humanized/adverse effects, Antineoplastic Agents/adverse effects, Antineoplastic Agents/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carcinoma, Renal Cell/drug therapy, Carcinoma, Renal Cell/mortality, Everolimus/administration & dosage, Everolimus/adverse effects, Female, Humans, Kidney Neoplasms/drug therapy, Kidney Neoplasms/mortality, Male, Middle Aged, Phenylurea Compounds/administration & dosage, Phenylurea Compounds/adverse effects, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Progression-Free Survival, Protein Kinase Inhibitors/therapeutic use, Quinolines/administration & dosage, Quinolines/adverse effects, Sunitinib/adverse effects, Sunitinib/therapeutic use, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Kidney Neoplasms, Medicine (all), General Medicine, Human health sciences, Oncology, Sciences de la santé humaine, Oncologie
العلاقة: http://www.nejm.org/doi/pdf/10.1056/NEJMoa2035716Test; urn:issn:0028-4793; urn:issn:1533-4406
الوصول الحر: https://orbi.uliege.be/handle/2268/300816Test
-
2دورية أكاديمية
المؤلفون: Henrotin, Yves, de Leval, X., Mathy, Marianne, Mouithys-Mickalad, Ange, Deby, Ginette, Dogné, Jean-Michel, Delarge, J., Reginster, Jean-Yves
المصدر: Inflammation Research, 50 (8), 391-9 (2001)
مصطلحات موضوعية: Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal/pharmacology, Cells, Cultured, Chondrocytes/drug effects/metabolism, Cyclooxygenase 1, Cyclooxygenase 2, Cyclooxygenase 2 Inhibitors, Cyclooxygenase Inhibitors/pharmacology, Cytokines/metabolism, DNA/biosynthesis/genetics, Diclofenac/analogs & derivatives/pharmacology, Dinoprostone/metabolism, Humans, Inflammation Mediators/metabolism, Interleukin-1/biosynthesis/genetics, Isoenzymes/metabolism, Membrane Proteins, Middle Aged, Nitric Oxide/metabolism, Nitric Oxide Synthase/biosynthesis/genetics, Nitric Oxide Synthase Type II, Prostaglandin-Endoperoxide Synthases/metabolism, Reverse Transcriptase Polymerase Chain Reaction, Human health sciences, Rheumatology, Sciences de la santé humaine, Rhumatologie
العلاقة: urn:issn:1023-3830; urn:issn:1420-908X
الوصول الحر: https://orbi.uliege.be/handle/2268/10412Test